Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

209 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial.
Wen PY, Stein A, van den Bent M, De Greve J, Wick A, de Vos FYFL, von Bubnoff N, van Linde ME, Lai A, Prager GW, Campone M, Fasolo A, Lopez-Martin JA, Kim TM, Mason WP, Hofheinz RD, Blay JY, Cho DC, Gazzah A, Pouessel D, Yachnin J, Boran A, Burgess P, Ilankumaran P, Gasal E, Subbiah V. Wen PY, et al. Among authors: de greve j, de vos fyfl. Lancet Oncol. 2022 Jan;23(1):53-64. doi: 10.1016/S1470-2045(21)00578-7. Epub 2021 Nov 24. Lancet Oncol. 2022. PMID: 34838156 Clinical Trial.
Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma.
Neyns B, Sadones J, Joosens E, Bouttens F, Verbeke L, Baurain JF, D'Hondt L, Strauven T, Chaskis C, In't Veld P, Michotte A, De Greve J. Neyns B, et al. Among authors: de greve j. Ann Oncol. 2009 Sep;20(9):1596-1603. doi: 10.1093/annonc/mdp032. Epub 2009 Jun 2. Ann Oncol. 2009. PMID: 19491283 Free article. Clinical Trial.
Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI).
Schöffski P, Blay JY, De Greve J, Brain E, Machiels JP, Soria JC, Sleijfer S, Wolter P, Ray-Coquard I, Fontaine C, Munzert G, Fritsch H, Hanft G, Aerts C, Rapion J, Allgeier A, Bogaerts J, Lacombe D. Schöffski P, et al. Among authors: de greve j. Eur J Cancer. 2010 Aug;46(12):2206-15. doi: 10.1016/j.ejca.2010.03.039. Epub 2010 May 13. Eur J Cancer. 2010. PMID: 20471824 Clinical Trial.
Phase II study of sunitinib malate in patients with recurrent high-grade glioma.
Neyns B, Sadones J, Chaskis C, Dujardin M, Everaert H, Lv S, Duerinck J, Tynninen O, Nupponen N, Michotte A, De Greve J. Neyns B, et al. Among authors: de greve j. J Neurooncol. 2011 Jul;103(3):491-501. doi: 10.1007/s11060-010-0402-7. Epub 2010 Sep 25. J Neurooncol. 2011. PMID: 20872043 Clinical Trial.
An observational study of the first experience with bevacizumab for the treatment of patients with recurrent high-grade glioma in two belgian university hospitals.
Huylebrouck M, Lv S, Duerinck J, Van Binst A, Salmon I, De Greve J, De Witte O, Luce S, Michotte A, D'Haens J, Neyns B. Huylebrouck M, et al. Among authors: de greve j, de witte o. J Oncol. 2012;2012:801306. doi: 10.1155/2012/801306. Epub 2012 Mar 13. J Oncol. 2012. PMID: 22481934 Free PMC article.
Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab.
Lv S, Teugels E, Sadones J, De Brakeleer S, Duerinck J, Du Four S, Michotte A, De Grève J, Neyns B. Lv S, et al. Among authors: de brakeleer s, de greve j. Int J Oncol. 2012 Sep;41(3):1029-35. doi: 10.3892/ijo.2012.1539. Epub 2012 Jun 29. Int J Oncol. 2012. PMID: 22752145 Clinical Trial.
Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours.
Plummer R, Verheul HM, De Vos FYFL, Leunen K, Molife LR, Rolfo C, Grundtvig-Sørensen P, De Grève J, Rottey S, Jerusalem G, Italiano A, Spicer J, Dirix L, Goessl C, Birkett J, Spencer S, Learoyd M, Bailey C, Dean E. Plummer R, et al. Among authors: de vos fyfl, de greve j. Adv Ther. 2018 Nov;35(11):1945-1964. doi: 10.1007/s12325-018-0804-z. Epub 2018 Oct 15. Adv Ther. 2018. PMID: 30324586 Clinical Trial.
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T; PERUSE investigators. Miles D, et al. Ann Oncol. 2021 Oct;32(10):1245-1255. doi: 10.1016/j.annonc.2021.06.024. Epub 2021 Jul 2. Ann Oncol. 2021. PMID: 34224826 Free article. Clinical Trial.
Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia.
Kreitman RJ, Moreau P, Ravandi F, Hutchings M, Gazzah A, Michallet AS, Wainberg ZA, Stein A, Dietrich S, de Jonge MJA, Willenbacher W, De Grève J, Arons E, Ilankumaran P, Burgess P, Gasal E, Subbiah V. Kreitman RJ, et al. Among authors: de greve j. Blood. 2023 Mar 2;141(9):996-1006. doi: 10.1182/blood.2021013658. Blood. 2023. PMID: 36108341 Free PMC article.
A single-blind, randomised, vehicle-controlled dose-finding study of recombinant human granulocyte colony-stimulating factor (lenograstim) in patients undergoing chemotherapy for solid cancers and lymphoma.
Seymour AM, de Campos E, Thatcher N, De Greve J, Cunningham D, Howell A, Tueni E, Bron DG, Steward WP, Berdel WE, et al. Seymour AM, et al. Among authors: de greve j, de campos e. Eur J Cancer. 1995 Dec;31A(13-14):2157-63. doi: 10.1016/0959-8049(95)00197-2. Eur J Cancer. 1995. PMID: 8652235 Clinical Trial.
209 results